<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INDOMETHACIN- indomethacin capsule </strong><br>Contract Pharmacy Services-PA<br></p></div>
<h1>INDOMETHACIN CAPSULES, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6cec5797-b61a-4402-87bf-d3ecebac0f5e"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">25 mg and 50 mg</span></p>
</div>
<div class="Warning">
<a name="id_03872ffb-3e5a-4bf4-8704-2bdf9445a534"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First">Cardiovascular Risk</p>
<ul>
<li>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</li>
<li>Indomethacin is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</li>
</ul>
<p>Gastrointestinal Risk</p>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</li></ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_5a3e57c5-6033-4c17-b1a0-9d3ef3a9ac16"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Indomethacin Capsules, USP for oral administration are provided in two dosage strengths which contain either 25 mg or 50 mg of indomethacin. Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1<span class="Italics">H</span>-indole-3-acetic acid.</p>
<p>The structural formula is:</p>
<div class="Figure">
<img alt="Structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d5df05a-f4af-48d8-b880-97dfb92e900c&amp;name=3d5df05a-f4af-48d8-b880-97dfb92e900c-01.jpg"><p class="MultiMediaCaption">C<span class="Sub">19</span>H<span class="Sub">16</span>ClNO<span class="Sub">4</span>       M.W. 357.79</p>
</div>
<p>Indomethacin, USP is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali.</p>
<p>Each capsule for oral administration contains 25 mg or 50 mg of indomethacin and the following inactive ingredients: colloidal silicon dioxide, gelatin, FD&amp;C Green No. 3, magnesium stearate, microcrystalline cellulose, powdered cellulose, sodium lauryl sulfate, sodium starch glycolate, titanium dioxide and D&amp;C Yellow No. 10.</p>
<p>The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, pharmaceutical glaze and propylene glycol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_571ac66e-bcf4-4607-be38-c4dbd9535223"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) that exhibits antipyretic and analgesic properties. Its mode of action, like that of other anti-inflammatory drugs, is not known. However, its therapeutic action is not due to pituitary-adrenal stimulation.</p>
<p>Indomethacin is a potent inhibitor of prostaglandin synthesis <span class="Italics">in vitro.</span> Concentrations are reached during therapy which have been demonstrated to have an effect <span class="Italics">in vivo</span> as well. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in animal models. Moreover, prostaglandins are known to be among the mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Since indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.</p>
<p>Indomethacin has been shown to be an effective anti-inflammatory agent, appropriate for long-term use in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>, and <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</p>
<p>Indomethacin affords relief of symptoms; it does not alter the progressive course of the underlying disease.</p>
<p>Indomethacin suppresses <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> as demonstrated by relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, and reduction of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>. Improvement in patients treated with indomethacin for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> has been demonstrated by a reduction in <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, average number of joints involved, and morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>; by increased mobility as demonstrated by a decrease in walking time; and by improved functional capability as demonstrated by an increase in grip strength. Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more severe forms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects.</p>
<p>Indomethacin has been reported to diminish basal and CO<span class="Sub">2</span> stimulated cerebral blood flow in healthy volunteers following acute oral and intravenous administration. In one study, after one week of treatment with orally administered indomethacin, this effect on basal cerebral blood flow had disappeared. The clinical significance of this effect has not been established.</p>
<p>Indomethacin capsules have been found effective in relieving the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, reducing the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> of acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span> (see <a href="#i4i_indications_id_96753aaa-e43b-454e-8ace-1fd455273b7e">INDICATIONS AND USAGE</a>).</p>
<p>Following single oral doses of indomethacin capsules 25 mg or 50 mg, indomethacin is readily absorbed, attaining peak plasma concentrations of about 1 and 2 mcg/mL, respectively, at about 2 hours. Orally administered indomethacin capsules are virtually 100% bioavailable, with 90% of the dose absorbed within 4 hours. A single 50 mg dose of indomethacin oral suspension was found to be bioequivalent to a 50 mg indomethacin capsule when each was administered with food.</p>
<p>Indomethacin is eliminated via renal excretion, metabolism, and biliary excretion. Indomethacin undergoes appreciable enterohepatic circulation. The mean half-life of indomethacin is estimated to be about 4.5 hours. With a typical therapeutic regimen of 25 mg or 50 mg t.i.d., the steady-state plasma concentrations of indomethacin are an average 1.4 times those following the first dose.</p>
<p>Indomethacin exists in the plasma as the parent drug and its desmethyl, desbenzoyl, and desmethyl-desbenzoyl metabolites, all in the unconjugated form. About 60% of an oral dosage is recovered in urine as drug and metabolites (26% as indomethacin and its glucuronide), and 33% is recovered in feces (1.5% as indomethacin).</p>
<p>About 99% of indomethacin is bound to protein in plasma over the expected range of therapeutic plasma concentrations. Indomethacin has been found to cross the blood-brain barrier and the placenta.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_96753aaa-e43b-454e-8ace-1fd455273b7e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</p>
<p>Indomethacin has been found effective in active stages of the following:</p>
<ol>
<li>Moderate to severe <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> including acute flares of chronic disease.</li>
<li>Moderate to severe <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>.</li>
<li>Moderate to severe <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</li>
<li>Acute painful shoulder (<span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> and/or <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>).</li>
<li>Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_91ff48c6-6783-43af-ac64-8177bab6f598"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Indomethacin is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to indomethacin or the excipients (see <a href="#i4i_description_id_5a3e57c5-6033-4c17-b1a0-9d3ef3a9ac16">DESCRIPTION</a>).</p>
<p>Indomethacin should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to NSAIDs have been reported in such patients (see <a href="#i4i_section_id_5dd68134-ec24-4092-ad3b-a0542d2ff84a">WARNINGS: Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a>, and <a href="#i4i_section_id_252d4256-06a6-4387-8f52-2c8fd1edd070">PRECAUTIONS: General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a>).</p>
<p>Indomethacin is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f2fe06d-ac37-402e-b497-72592a8d8737"></a><a name="section-6.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f815f0b-b0c0-43a1-aba1-7ff5142b2a39"></a><a name="section-6.1.1"></a><p></p>
<h3>Cardiovascular Thrombotic Events</h3>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <a href="#i4i_section_id_ed1c85e1-2bd0-4d61-80e1-91b3f7a9a7c4">WARNINGS: Gastrointestinal Effects</a>).</p>
<p>Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <a href="#i4i_contraindications_id_91ff48c6-6783-43af-ac64-8177bab6f598">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5691e7ad-d6aa-4917-b2f1-8378536321f5"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">NSAIDs, including indomethacin, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including indomethacin, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b707a221-5fd6-4c04-ac80-7dcfb59bb0a2"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Indomethacin should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
<p>In a study of patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, indomethacin was associated with significant deterioration of circulatory hemodynamics, presumably due to inhibition of prostaglandin dependent compensatory mechanisms.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ed1c85e1-2bd0-4d61-80e1-91b3f7a9a7c4"></a><a name="section-6.2"></a><p></p>
<h2>Gastrointestinal Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cddb93e1-3706-4cf4-9456-22087cfa5afa"></a><a name="section-6.2.1"></a><p></p>
<h3>Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h3>
<p class="First">NSAIDs, including indomethacin, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2 to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p>Rarely, in patients taking indomethacin, <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span> has been associated with stenosis and obstruction. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> without obvious <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> formation and perforation of preexisting sigmoid lesions (<span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulum</span>, carcinoma, etc.) have occurred. Increased <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients or the development of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span> have been reported to occur rarely.</p>
<p>NSAIDs should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a <span class="Italics">prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span></span> who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients with neither of these risk factors. Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.</p>
<p>To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a920fdc-efe9-4206-bae8-0475261d8aa7"></a><a name="section-6.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate over renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, patients with <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<p>Increases in serum potassium concentration, including <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, have been reported with use of indomethacin, even in some patients without <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In patients with normal renal function, these effects have been attributed to a hyporeninemic-<span class="product-label-link" type="condition" conceptid="4028929" conceptname="Hyperreninemic hypoaldosteronism">hypoaldosteronism</span> state (see <a href="#i4i_interactions_id_f67a7810-cf75-4cc6-aa29-9a771fb781e1">PRECAUTIONS: Drug Interactions</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_73f905d2-2e6c-4139-bae1-69244ae90c84"></a><a name="section-6.3.1"></a><p></p>
<h3>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h3>
<p class="First">No information is available from controlled clinical studies regarding the use of indomethacin in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with indomethacin is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If indomethacin therapy must be initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5dd68134-ec24-4092-ad3b-a0542d2ff84a"></a><a name="section-6.4"></a><p></p>
<h2>Anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to indomethacin. Indomethacin should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <a href="#i4i_contraindications_id_91ff48c6-6783-43af-ac64-8177bab6f598">CONTRAINDICATIONS</a> and <a href="#i4i_section_id_252d4256-06a6-4387-8f52-2c8fd1edd070">PRECAUTIONS: General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a>). Emergency help should be sought in cases where an anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58280b0b-af09-492e-9eef-0162788cc741"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">NSAIDs, including indomethacin, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9892bac2-1a73-42bd-8746-6c1d94f244fd"></a><a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, indomethacin should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_294598f0-743d-43b7-ab92-09e0768613e6"></a><a name="section-6.7"></a><p></p>
<h2>Ocular Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">Corneal deposits</span> and retinal disturbances, including those of the macula, have been observed in some patients who had received prolonged therapy with indomethacin. The prescribing physician should be alert to the possible association between the changes noted and indomethacin. It is advisable to discontinue therapy if such changes are observed. <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> may be a significant symptom and warrants a thorough ophthalmological examination. Since these changes may be asymptomatic, ophthalmologic examination at periodic intervals is desirable in patients where therapy is prolonged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c41f627b-26fc-4757-b9f1-93058c2d7ef8"></a><a name="section-6.8"></a><p></p>
<h2>Central Nervous System Effects</h2>
<p class="First">Indomethacin may aggravate <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other psychiatric disturbances, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, and should be used with considerable caution in patients with these conditions. If severe CNS adverse reactions develop, indomethacin should be discontinued.</p>
<p>Indomethacin may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>; therefore, patients should be cautioned about engaging in activities requiring mental alertness and motor coordination, such as driving a car. Indomethacin may also cause <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> which persists despite dosage reduction requires cessation of therapy with indomethacin.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_567f1ba5-8b31-47b6-ad64-b4e3b5543be9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_b0ff80f3-c3d8-40f1-9541-8011aec507fe"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Indomethacin cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
<p>The pharmacological activity of indomethacin in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_01fc2be4-2756-4929-aba3-27257c3869ae"></a><a name="section-7.1.1"></a><p></p>
<h3>Hepatic Effects</h3>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, including indomethacin. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test values has occured, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with indomethacin. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), indomethacin should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be033cf9-9cf4-40c7-b419-d2e3d5dda4c6"></a><a name="section-7.1.2"></a><p></p>
<h3>Hematological Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including indomethacin. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including indomethacin, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p>NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving indomethacin who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_252d4256-06a6-4387-8f52-2c8fd1edd070"></a><a name="section-7.1.3"></a><p></p>
<h3>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross-reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, indomethacin should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_6f61c7a4-61d2-46a3-b55a-1096662377b9"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First"><span class="Bold">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed</span>.</p>
<ol>
<li>Indomethacin, like other NSAIDs, may cause serious CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_section_id_0f2fe06d-ac37-402e-b497-72592a8d8737">WARNINGS: Cardiovascular Effects</a>).</li>
<li>Indomethacin, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative signs or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_section_id_cddb93e1-3706-4cf4-9456-22087cfa5afa">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a>).</li>
<li>Indomethacin, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.</li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g. <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</li>
<li>In late pregnancy, as with other NSAIDs, indomethacin should be avoided because it may cause premature closure of the ductus arteriosus.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_d12a5c91-6e81-4533-8bfb-df35f4004958"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or if abnormal liver tests persist or worsen, indomethacin should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_f67a7810-cf75-4cc6-aa29-9a771fb781e1"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7a48583b-2b3c-49cf-accd-345cf2f76a43"></a><a name="section-7.4.1"></a><p></p>
<h3>ACE Inhibitors and Angiotensin II Antagonists</h3>
<p class="First">Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and angiotensin II antagonists. Indomethacin can reduce the antihypertensive effects of captopril and losartan. These interactions should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors or angiotensin II antagonists. In some patients with compromised renal function, the coadministration of an NSAID and an ACE inhibitor or an angiotensin II antagonist may result in further deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, which is usually reversible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fd20a58b-71c9-4c98-9a5f-53b03bf93c88"></a><a name="section-7.4.2"></a><p></p>
<h3>Aspirin</h3>
<p class="First">When indomethacin is administered with aspirin, its protein binding is reduced, although the clearance of free indomethacin is not altered. The clinical significance of this interaction is not known.</p>
<p>The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not produce any greater therapeutic effect than the use of indomethacin alone. In a clinical study of the combined use of indomethacin and aspirin, the incidence of gastrointestinal side effects was significantly increased with combined therapy.</p>
<p>In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of aspirin per day decreases indomethacin blood levels approximately 20%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b18bbae-f76a-4713-8ff0-116545a75cb0"></a><a name="section-7.4.3"></a><p></p>
<h3>Beta-Adrenoceptor Blocking Agents</h3>
<p class="First">Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by non-steroidal anti-inflammatory drugs including indomethacin has been reported. Therefore, when using these blocking agents to treat <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, patients should be observed carefully in order to confirm that the desired therapeutic effect has been obtained.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b9c6b32-5c0b-4369-bd84-d86ad598784e"></a><a name="section-7.4.4"></a><p></p>
<h3>Cyclosporin</h3>
<p class="First">Administration of non-steroidal anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin. NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7744223d-c47c-4c20-94c8-b5bff29f1a74"></a><a name="section-7.4.5"></a><p></p>
<h3>Diflunisal</h3>
<p class="First">In normal volunteers receiving indomethacin, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of indomethacin. In some patients, combined use of indomethacin and diflunisal has been associated with fatal <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>. Therefore, diflunisal and indomethacin should not be used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dfde056e-31ae-4abe-a40c-442d5301187d"></a><a name="section-7.4.6"></a><p></p>
<h3>Digoxin</h3>
<p class="First">Indomethacin given concomitantly with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. Therefore, when indomethacin and digoxin are used concomitantly, serum digoxin levels should be closely monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5c88b4e-b349-49ed-b946-6bc6913253d7"></a><a name="section-7.4.7"></a><p></p>
<h3>Diuretics</h3>
<p class="First">In some patients, the administration of indomethacin can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing, and thiazide diuretics. This response has been attributed to inhibition of renal prostaglandin synthesis.</p>
<p>Indomethacin reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by furosemide administration, or salt or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. These facts should be considered when evaluating plasma renin activity in hypertensive patients.</p>
<p>It has been reported that the addition of triamterene to a maintenance schedule of indomethacin resulted in reversible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> in two of four healthy volunteers. Indomethacin and triamterene should not be administered together.</p>
<p>Indomethacin and potassium-sparing diuretics each may be associated with increased serum potassium levels. The potential effects of indomethacin and potassium-sparing diuretics on potassium kinetics and renal function should be considered when these agents are administered concurrently. Most of the above effects concerning diuretics have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by indomethacin.</p>
<p>During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#i4i_section_id_2a920fdc-efe9-4206-bae8-0475261d8aa7">WARNINGS: Renal Effects</a>), as well as to assure diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bdf45ccf-ad0a-4753-9c6d-839e42e6183d"></a><a name="section-7.4.8"></a><p></p>
<h3>Lithium</h3>
<p class="First">Indomethacin capsules 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady-state plasma lithium concentrations. This effect has been attributed to inhibition of prostaglandin synthesis. As a consequence, when NSAIDs and lithium are given concomitantly, the patient should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. (Read circulars for lithium preparations before use of such concomitant therapy.) In addition, the frequency of monitoring serum lithium concentration should be increased at the outset of such combination drug treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8cb3c8e9-a040-4105-bf08-52d617f9849c"></a><a name="section-7.4.9"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_262549ed-0ffe-49af-a409-8e235d871cb0"></a><a name="section-7.4.10"></a><p></p>
<h3>NSAIDs</h3>
<p class="First">The concomitant use of indomethacin with other NSAIDs is not recommended due to the increased possibility of <span class="product-label-link" type="condition" conceptid="197596" conceptname="Toxic gastroenteritis">gastrointestinal toxicity</span>, with little or no increase in efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c32a67b8-1e17-4411-a944-9d3fb273b66a"></a><a name="section-7.4.11"></a><p></p>
<h3>Oral anticoagulants</h3>
<p class="First">Clinical studies have shown that indomethacin does not influence the <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span> produced by anticoagulants. However, when any additional drug, including indomethacin, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. In post-marketing experience, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in patients on concomitant treatment with anticoagulants and indomethacin. Caution should be exercised when indomethacin and anticoagulants are administered concomitantly. The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c30cc0fe-9974-4149-94a1-d7f41fba1fa6"></a><a name="section-7.4.12"></a><p></p>
<h3>Probenecid</h3>
<p class="First">When indomethacin is given to patients receiving probenecid, the plasma levels of indomethacin are likely to be increased. Therefore, a lower total daily dosage of indomethacin may produce a satisfactory therapeutic effect. When increases in the dose of indomethacin are made, they should be made carefully and in small increments.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_b21419bd-b245-4f49-a6ef-6b18a9267a61"></a><a name="section-7.5"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">False-negative results in the <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> (DST) in patients being treated with indomethacin have been reported. Thus, results of the DST should be interpreted with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_a8be4568-3bb9-452b-a702-fe65fd4a474a"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In an 81-week chronic oral toxicity study in the rat at doses up to 1 mg/kg/day, indomethacin had no tumorigenic effect.</p>
<p>Indomethacin produced no neoplastic or hyperplastic changes related to treatment in carcinogenic studies in the rat (dosing period 73 to 110 weeks) and the mouse (dosing period 62 to 88 weeks) at doses up to 1.5 mg/kg/day.</p>
<p>Indomethacin did not have any mutagenic effect in <span class="Italics">in vitro</span> bacterial tests (Ames test and <span class="Italics">E. coli</span> with or without metabolic activation) and a series of <span class="Italics">in vivo</span> tests including the host-mediated assay, sex-linked recessive lethals in <span class="Italics">Drosophila</span>, and the micronucleus test in mice.</p>
<p>Indomethacin at dosage levels up to 0.5 mg/kg/day had no effect on fertility in mice in a two generation reproduction study or a two litter reproduction study in rats.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_aa3aec19-1ffe-4f87-8bc1-469ac1a56307"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_41ec122a-6f83-4a67-8046-14cd3eaf490d"></a><a name="section-7.7.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category C</h3>
<p class="First">Teratogenic studies were conducted in mice and rats at dosages of 0.5, 1.0, 2.0, and 4.0 mg/kg/day. Except for retarded fetal ossification at 4 mg/kg/day considered secondary to the decreased average fetal weights, no increase in <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> was observed as compared with control groups. Other studies in mice reported in the literature using higher doses (5 to 15 mg/kg/day) have described maternal toxicity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, increased fetal resorptions, and <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Comparable studies in rodents using high doses of aspirin have shown similar maternal and fetal effects. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women.</p>
<p>Indomethacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_d81924be-70c2-476f-92a9-eb2e2aad30f0"></a><a name="section-7.7.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided.</p>
<p>The known effects of indomethacin and other drugs of this class on the human fetus during the third trimester of pregnancy include: constriction of the ductus arteriosus prenatally, <span class="product-label-link" type="condition" conceptid="4006971" conceptname="Tricuspid valve regurgitation">tricuspid incompetence</span>, and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; nonclosure of the ductus arteriosus postnatally which may be resistant to medical management; myocardial degenerative changes, platelet dysfunction with resultant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, renal dysfunction or failure, <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>/dysgenesis which may result in prolonged or permanent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or perforation, and increased risk of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.</p>
<p>In rats and mice, 4.0 mg/kg/day given during the last 3 days of gestation caused a decrease in maternal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and some maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>. An increased incidence of neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in the diencephalon in the live born fetuses was observed. At 2.0 mg/kg/day, no increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> was observed as compared to the control groups. Administration of 0.5 or 4.0 mg/kg/day during the first 3 days of life did not cause an increase in neuronal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at either dose level.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_3b740679-5a81-4124-a867-83a92caa480c"></a><a name="section-7.8"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">In rat studies with NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of indomethacin on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_b3637655-4367-4ee4-b695-039572ae5671"></a><a name="section-7.9"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Indomethacin is excreted in the milk of lactating mothers. Indomethacin is not recommended for use in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ba34de4d-c76d-409f-b025-76afd82e6254"></a><a name="section-7.10"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients 14 years of age and younger have not been established.</p>
<p>Indomethacin should not be prescribed for pediatric patients 14 years of age and younger unless toxicity or lack of efficacy associated with other drugs warrants the risk.</p>
<p>In experience with more than 900 pediatric patients reported in the literature or to the manufacturer who were treated with Capsules indomethacin, side effects in pediatric patients were comparable to those reported in adults. Experience in pediatric patients has been confined to the use of Capsules indomethacin.</p>
<p>If a decision is made to use indomethacin for pediatric patients 2 years of age or older, such patients should be monitored closely and periodic assessment of liver function is recommended. There have been cases of hepatotoxicity reported in pediatric patients with <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span>, including fatalities. If indomethacin treatment is instituted, a suggested starting dose is 1 to 2 mg/kg/day given in divided doses. Maximum daily dosage should not exceed 3 mg/kg/day or 150 to 200 mg/day, whichever is less. Limited data are available to support the use of a maximum daily dosage of 4mg/kg/day or 150 to 200 mg/day, whichever is less. As symptoms subside, the total daily dosage should be reduced to the lowest level required to control symptoms, or the drug should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_1fab80c3-fa65-4712-a318-76bd54aab079"></a><a name="section-7.11"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">As with any NSAID, caution should be exercised in treating the elderly (65 years and older) since advancing age appears to increase the possibility of adverse reactions (see <a href="#i4i_section_id_cddb93e1-3706-4cf4-9456-22087cfa5afa">WARNINGS, Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a> and <a href="#i4i_dosage_admin_id_95e479d3-109a-44ea-89a4-33eaf5e9b13d">DOSAGE AND ADMINISTRATION</a>). Elderly patients seem to tolerate ulceration or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> less well than other individuals and many spontaneous reports of fatal GI events are in this population (see <a href="#i4i_section_id_ed1c85e1-2bd0-4d61-80e1-91b3f7a9a7c4">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a>).</p>
<p>Indomethacin may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or, rarely, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> (see <a href="#i4i_adverse_effects_id_72d0aff7-66b4-404c-9021-4809714bd7e1">ADVERSE REACTIONS</a>); physicians should remain alert to the possibility of such adverse effects in the elderly.</p>
<p>This drug is known to be substantially excreted by the kidney and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and it may be useful to monitor renal function (see <a href="#i4i_section_id_2a920fdc-efe9-4206-bae8-0475261d8aa7">WARNINGS: Renal Effects</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_72d0aff7-66b4-404c-9021-4809714bd7e1"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The adverse reactions for indomethacin capsules listed in the following table have been arranged into two groups: (1) incidence greater than 1%; and (2) incidence less than 1%. The incidence for group (1) was obtained from 33 double-blind controlled clinical trials reported in the literature (1,092 patients). The incidence for group (2) was based on reports in clinical trials, in the literature, and on voluntary reports since marketing. The probability of a causal relationship exists between indomethacin and these adverse reactions, some of which have been reported only rarely.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1552708f-9f40-4f2a-aebf-04de3fd629c9"></a><a name="section-8.1"></a><p></p>
<div class="Warning">
<a name="id_19b5c90a-7f9d-4a9c-856d-5347512d5664"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Incidence greater than 1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_059a3756-3bfd-4e12-87d0-f3827f0648c8"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">GASTROINTESTINAL</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> with or without <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a> (including <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>)<br><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span><br><span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span><br><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></p>
<p><span class="Italics">CENTRAL NERVOUS SYSTEM</span><br><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (11.7%)<br><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a><br><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span><br><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span><br><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (including <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>)</p>
<p><span class="Italics">SPECIAL SENSES</span><br><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="Italics">CARDIOVASCULAR</span><br>none</p>
<p><span class="Italics">METABOLIC</span><br>none</p>
<p><span class="Italics">INTEGUMENTARY</span><br>none</p>
<p><span class="Italics">HEMATOLOGIC</span><br>none</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span></span><br>none</p>
<p><span class="Italics">GENITOURINARY</span><br>none</p>
<p><span class="Italics">MISCELLANEOUS</span><br>none</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><p class="First">Reactions occurring in 3% to 9% of patients treated with indomethacin. (Those reactions occurring in less than 3% of the patients are unmarked.)</p></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd><p class="First">Reactions occurring in 3% to 9% of patients treated with indomethacin. (Those reactions occurring in less than 3% of the patients are unmarked.)</p></dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd><p class="First">Reactions occurring in 3% to 9% of patients treated with indomethacin. (Those reactions occurring in less than 3% of the patients are unmarked.)</p></dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d0e46e3-57ed-4845-aab9-59b64d7d393a"></a><a name="section-8.2"></a><p></p>
<div class="Warning">
<a name="id_22885137-815d-4366-a6e4-50d9e0cdd8b3"></a><a name="section-8.2.1"></a><p></p>
<p class="First">Incidence less than 1%</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a7003a8-f593-4c34-8769-a5e1794113bc"></a><a name="section-8.2.1"></a><p></p>
<p class="First"><span class="Italics">GASTROINTESTINAL</span><br><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span><br><span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span> (includes <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>)<br><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span><br><span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span><br><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span><br><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span><br><span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span><br>single or multiple ulcerations, including perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> of the esophagus, stomach, duodenum or small and large intestines<br><span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulceration</span> associated with stenosis and obstruction<br><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> without obvious <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> formation and perforation of preexisting sigmoid lesions (<span class="product-label-link" type="condition" conceptid="4150051" conceptname="Diverticulum">diverticulum</span>, carcinoma, etc.) development of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> and regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span><br><span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span><br>toxic <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (some fatal cases have been reported)<br><span class="product-label-link" type="condition" conceptid="4044413" conceptname="Stenosis of intestine">intestinal strictures</span> (diaphragms)</p>
<p><span class="Italics">CENTRAL NERVOUS SYSTEM</span><br><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (includes <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>)<br><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span><br><span class="product-label-link" type="condition" conceptid="4319906" conceptname="Dyskinesia">involuntary muscle movements</span><br><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span><br>muzziness<br><span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic episodes</span><br><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span><br><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span><br>light-headedness<br><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span><br><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span><br>aggravation of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span><br><span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span><br><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span><br><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span><br><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span></p>
<p><span class="Italics">SPECIAL SENSES</span><br>ocular-<span class="product-label-link" type="condition" conceptid="4080669" conceptname="Keratic precipitates">corneal deposits</span> and retinal disturbances, including those of the macula, have been reported in some patients on prolonged therapy with indomethacin<br><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span><br><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span><br>hearing disturbances, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span></p>
<p><span class="Italics">CARDIOVASCULAR</span><br><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span><br><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span><br><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span><br><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span><br><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span><br><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Italics">METABOLIC</span><br><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span><br><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span><br><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span><br><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span><br><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span><br><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span><br><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span></p>
<p><span class="Italics">INTEGUMENTARY</span><br><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><br><span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> or <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span><br><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span><br><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span><br>loss of hair<br><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span><br><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span><br><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p><span class="Italics">HEMATOLOGIC</span><br><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span><br><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span><br><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> secondary to obvious or occult <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span><br><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span><br><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span><br><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span><br><span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span><br><span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span></span><br><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">acute anaphylaxis</span><br>acute <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span><br>rapid <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> resembling a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like state<br><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span><br><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span><br><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span><br><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span><br><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span><br><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></p>
<p><span class="Italics">GENITOURINARY</span><br><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span><br><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span><br><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span><br>BUN elevation<br><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></p>
<p><span class="Italics">MISCELLANEOUS</span><br><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span><br>breast changes, including enlargement and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce797ddf-7400-45e6-bb15-f40a17d60e3c"></a><a name="section-8.3"></a><p></p>
<h2>Causal Relationship Unknown</h2>
<p class="First">Other reactions have been reported but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, the possibility cannot be excluded. Therefore, these observations are being listed to serve as alerting information to physicians:</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span></p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> Although there have been several reports of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, the supporting information is weak.</p>
<p><span class="Bold"><span class="Italics">Genitourinary:</span></span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span></p>
<p>A rare occurrence of fulminant <span class="product-label-link" type="condition" conceptid="133566" conceptname="Necrotizing fasciitis">necrotizing fasciitis</span>, particularly in association with Group A β-hemolytic streptococcus, has been described in persons treated with non-steroidal anti-inflammatory agents, including indomethacin, sometimes with fatal outcome (see also <a href="#i4i_precautions_general_id_b0ff80f3-c3d8-40f1-9541-8011aec507fe">PRECAUTIONS: General</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a031bb01-aae5-4cfb-8140-3d5a8c2cac0c"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The following symptoms may be observed following overdosage: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, intense <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, or <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>. There have been reports of <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Treatment is symptomatic and supportive. The stomach should be emptied as quickly as possible if the ingestion is recent. If <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> has not occurred spontaneously, the patient should be induced to vomit with syrup of ipecac. If the patient is unable to vomit, gastric lavage should be performed. Once the stomach has been emptied, 25 g or 50 g of activated charcoal may be given. Depending on the condition of the patient, close medical observation and nursing care may be required. The patient should be followed for several days because gastrointestinal ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> have been reported as adverse reactions of indomethacin. Use of antacids may be helpful.</p>
<p>The oral LD<span class="Sub">50</span> of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_95e479d3-109a-44ea-89a4-33eaf5e9b13d"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of indomethacin and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</p>
<p>After observing the response to initial therapy with indomethacin, the dose and frequency should be adjusted to suit an individual patient's needs.</p>
<p>Indomethacin is available as 25 mg and 50 mg capsules.</p>
<p>Adverse reactions appear to correlate with the size of the dose of indomethacin in most patients but not all. Therefore, every effort should be made to determine the smallest effective dosage for the individual patient.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_508afdbb-3d21-4556-be2d-6c66523dbe76"></a><a name="section-10.1"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Indomethacin ordinarily should not be prescribed for pediatric patients 14 years of age and under (see <a href="#i4i_warnings_id_e08c39e2-9bf4-419c-8699-dd1ba98bbbe5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f26890a0-583f-46e2-8a5d-c612a94ac504"></a><a name="section-10.2"></a><p></p>
<h2>Adult Use</h2>
<p class="First">Dosage Recommendations for Active Stages of the Following:</p>
<ol><li>1.Moderate to severe <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> including acute flares of chronic disease; moderate to severe <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>; and moderate to severe <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.<br> <br>Suggested Dosage: Indomethacin capsules 25 mg b.i.d. or t.i.d. If this is well tolerated, increase the daily dosage by 25 mg or by 50 mg, if required by continuing symptoms, at weekly intervals until a satisfactory response is obtained or until a total daily dose of 150 mg to 200 mg is reached. DOSES ABOVE THIS AMOUNT GENERALLY DO NOT INCREASE THE EFFECTIVENESS OF THE DRUG.</li></ol>
<p>In patients who have persistent night <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, the giving of a large portion, up to a maximum of 100 mg, of the total daily dose at bedtime may be helpful in affording relief. The total daily dose should not exceed 200 mg. In acute flares of chronic <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, it may be necessary to increase the dosage by 25 mg or, if required, by 50 mg daily.</p>
<p>If minor adverse effects develop as the dosage is increased, reduce the dosage rapidly to a tolerated dose and OBSERVE THE PATIENT CLOSELY.</p>
<p>If severe adverse reactions occur, STOP THE DRUG. After the acute phase of the disease is under control, an attempt to reduce the daily dose should be made repeatedly until the patient is receiving the smallest effective dose or the drug is discontinued.</p>
<p>Careful instructions to, and observations of, the individual patient are essential to the prevention of serious, irreversible, including fatal, adverse reactions.</p>
<p>As advancing years appear to increase the possibility of adverse reactions, indomethacin should be used with greater care in the elderly (see <a href="#i4i_geriatric_use_id_1fab80c3-fa65-4712-a318-76bd54aab079">PRECAUTIONS: Geriatric Use</a>).</p>
<ul>
<li>2.Acute painful shoulder (<span class="product-label-link" type="condition" conceptid="134453" conceptname="Bursitis">bursitis</span> and/or <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendinitis</span>).<br> <br>Initial Dose: 75 mg to 150 mg daily in 3 or 4 divided doses. The drug should be discontinued after the signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> have been controlled for several days. The usual course of therapy is 7 to 14 days.<br> </li>
<li>3.Acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>.<br> <br>Suggested Dosage: Indomethacin capsules 50 mg t.i.d. until <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is tolerable. The dose should then be rapidly reduced to complete cessation of the drug. Definite relief of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> has been reported within 2 to 4 hours. <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span> and heat usually subside in 24 to 36 hours, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> gradually disappears in 3 to 5 days.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_4973077b-5acb-4db1-b115-9fe3cde138cb"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Indomethacin Capsules, USP are available containing either 25 mg or 50 mg of Indomethacin, USP.</p>
<p>The 25 mg capsule is a hard-shell gelatin capsule with a light green opaque cap and a light green opaque body axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">143</span> in black ink on both the cap and body. The capsule is filled with a white powder blend. They are available as follows:</p>
<p>NDC 67046-330-30<br><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> of 30 capsules</p>
<p>The 50 mg capsule is a hard-shell gelatin capsule with a light green opaque cap and a light green opaque body axially printed with <span class="Bold">MYLAN</span> over <span class="Bold">147</span> in black ink on both the cap and body. The capsule is filled with a white powder blend. They are available as follows:</p>
<p>NDC 67046-331-30<br><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> of 30 capsules</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_f1bad75c-f65f-4aeb-9f1c-5ff4748c99c3"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Medication Guide with each prescription.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ab82b37-9622-4b84-8d72-fb3997aceda4"></a><a name="section-12"></a><p></p>
<p class="First">Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED MARCH 2008<br>INDO:R26mc</p>
<p>Repackaged by:<br><br>Contract Pharmacy Services-PA<br>125 Titus Ave Suite 200<br>Warrington, PA 18976 USA</p>
<p>Original--07/2010--NJW</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_375d44a4-76ab-4d34-ad66-7db6cdb879ea"></a><a name="section-13"></a><p></p>
<h1>Medication Guide for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</h1>
<p class="First"><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<p><br><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<ul>
<li><p class="First"><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This chance increases:<br> <br> </p></li>
<li>
<span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a "coronary artery bypass graft (CABG)."</span><br> </li>
<li>
<br><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:<br> </span><br> </li>
<li>
<span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span><br> <br> </li>
<li>
<span class="Bold">NSAID medicines should only be used:</span><br> </li>
</ul>
<p><br><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as:</p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span></li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine:</span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine</li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist.</span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<a name="id_675d578a-9ef5-4c48-b69c-6bbaddb6a1e9"></a><table width="430.000">
<col align="left" width="60.0%">
<col align="left" width="40.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">Serious side effects include:</span></td>
<td align="left" valign="top"><span class="Bold">Other side effects include:</span></td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top"><ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul></td>
<td align="left" valign="top"><ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat</li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>more tired or weaker than usual</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></li>
<li>your skin or eyes look yellow</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li>flu-like symptoms</li>
<li>vomit blood</li>
<li>there is blood in your bowel movement or it is black and sticky like tar</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet</li>
</ul>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines.</p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<ul>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines. </li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<p><span class="Underline"><span class="Bold">NSAID medicines that need a prescription</span></span></p>
<a name="id_af791bdc-78a4-416d-aacf-72f3ca7f16ad"></a><table width="430.000">
<col align="left" width="30.0%">
<col align="left" width="70.0%">
<thead><tr class="Botrule First Last">
<td class="Rrule" align="left" valign="top"> Generic Name</td>
<td align="left" valign="top">Tradename</td>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Vicoprofen contains the same dose of ibuprofen as over-the-counter (OTC) NSAIDs, and is usually used for less than 10 days to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The OTC NSAID label warns that long term continuous use may increase the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Celecoxib</td>
<td align="left" valign="top">Celebrex</td>
</tr>
<tr>
<td align="left" valign="top">Diclofenac</td>
<td align="left" valign="top">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td align="left" valign="top">Diflunisal</td>
<td align="left" valign="top">Dolobid</td>
</tr>
<tr>
<td align="left" valign="top">Etodolac</td>
<td align="left" valign="top">Lodine, Lodine XL</td>
</tr>
<tr>
<td align="left" valign="top">Fenoprofen</td>
<td align="left" valign="top">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td align="left" valign="top">Flurbiprofen</td>
<td align="left" valign="top">Ansaid</td>
</tr>
<tr>
<td align="left" valign="top">Ibuprofen</td>
<td align="left" valign="top">Motrin, Tab-Profen, Vicoprofen<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> (combined with hydrocodone), Combunox (combined with oxycodone)</td>
</tr>
<tr>
<td align="left" valign="top">Indomethacin</td>
<td align="left" valign="top">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td align="left" valign="top">Ketoprofen</td>
<td align="left" valign="top">Oruvail</td>
</tr>
<tr>
<td align="left" valign="top">Ketorolac</td>
<td align="left" valign="top">Toradol</td>
</tr>
<tr>
<td align="left" valign="top">Mefenamic Acid</td>
<td align="left" valign="top">Ponstel</td>
</tr>
<tr>
<td align="left" valign="top">Meloxicam</td>
<td align="left" valign="top">Mobic</td>
</tr>
<tr>
<td align="left" valign="top">Nabumetone</td>
<td align="left" valign="top">Relafen</td>
</tr>
<tr>
<td align="left" valign="top">Naproxen</td>
<td align="left" valign="top">Naprosyn, Anaprox, Anaprox DS, EC-Naprosyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td align="left" valign="top">Oxaprozin</td>
<td align="left" valign="top">Daypro</td>
</tr>
<tr>
<td align="left" valign="top">Piroxicam</td>
<td align="left" valign="top">Feldene</td>
</tr>
<tr>
<td align="left" valign="top">Sulindac</td>
<td align="left" valign="top">Clinoril</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Tolmetin</td>
<td align="left" valign="top">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_33e0a9a5-7dd6-4618-814e-3a25c9c1f1e1"></a><a name="section-14"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<img alt="25 mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d5df05a-f4af-48d8-b880-97dfb92e900c&amp;name=3d5df05a-f4af-48d8-b880-97dfb92e900c-02.jpg"><p class="MultiMediaCaption">25 mg Capsules</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_c08d902c-60c3-4716-819d-1a69b0a659df"></a><a name="section-15"></a><p></p>
<h1>Principal Display Panel</h1>
<div class="Figure">
<img alt="50 mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d5df05a-f4af-48d8-b880-97dfb92e900c&amp;name=3d5df05a-f4af-48d8-b880-97dfb92e900c-03.jpg"><p class="MultiMediaCaption">50 mg Capsules</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INDOMETHACIN 		
					</strong><br><span class="contentTableReg">indomethacin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67046-330(NDC:0378-0143)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Indomethacin</strong> (Indomethacin) </td>
<td class="formItem">Indomethacin</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (Light Green opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;143</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67046-330-30</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018858</td>
<td class="formItem">07/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INDOMETHACIN 		
					</strong><br><span class="contentTableReg">indomethacin capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67046-331(NDC:0378-0147)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Indomethacin</strong> (Indomethacin) </td>
<td class="formItem">Indomethacin</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (Light Green opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;147</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67046-331-30</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070624</td>
<td class="formItem">07/30/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Contract Pharmacy Services-PA
							(945429777)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3d5df05a-f4af-48d8-b880-97dfb92e900c</div>
<div>Set id: 3d5df05a-f4af-48d8-b880-97dfb92e900c</div>
<div>Version: 1</div>
<div>Effective Time: 20100730</div>
</div>
</div> <div class="DistributorName">Contract Pharmacy Services-PA</div></p>
</body></html>
